- Open-label, single-arm, single-center, phase 2 study evaluating efficacy and safety of Lu-177-DOTATATE in the selected patient population divided into two cohorts: 1) SDHx cohort will include patients with the succinate dehydrogenase mutation, which is the most common and most aggressive genetic sub-group of patients with PHEO/PGL, and 2) apparent sporadic cohort which will include patients without a clear genetic mutation